This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Dani P. Bolognesi, PhD

JAMA. 1989;261(20):3007-3013.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE IMMUNE response that develops subsequent to infection with human immunodeficiency virus (HIV) consists of both humoral and cellular elements that, when assessed in vitro, can inhibit virus infection and lyse virus-infected target cells. If such activities were operative in vivo, one would expect that they would suppress virus replication and virus-induced cytopathic effects. The antiviral immune response may thus represent one of the primary host defense mechanisms responsible for the protracted asymptomatic phase of the disease, which, in most patients, can last several years. An important question to be answered for development of vaccine strategies against HIV is whether this response might be an effective barrier to HIV infection de novo. If the immune response can indeed control the virus even for a limited period, then the issue would not be whether it is possible to mount a protective immune response against HIV, but whether it may be necessary . . . [Full Text PDF of this Article]

Author Affiliations
From the Departments of Surgery and Microbiology and Immunology, Duke University Medical Center, Durham, NC.

Footnotes
Reprint requests to Departments of Surgery and Microbiology and Immunology, Duke University Medical Center, PO Box 2926, Durham, NC 27710 (Dr Bolognesi).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?